FDA Approval Strategy

  • Neuromodulation Medical Device
  • Regulatory Strategy | GTM Operations
  • Timeframe: 2025

To support a US market expansion, I evaluated FDA submission viability across multiple active clinical trials, synthesizing trial data, past approval precedents, and FDA guidelines to inform the approval strategy.

The Challenge

A pre-market neuromodulation medical device company needed a viable path to FDA approval for commercial sale in the US. Their existing 510(k) submission strategy had been flagged as high-risk due to insufficient predicate device similarity, leaving the regulatory roadmap undetermined. I was brought in to identify and evaluate a more defensible pathway.

The Work

  • Clinical trial viability assessment
  • FDA pathway analysis
    • 510(k)
    • De Novo
    • Breakthrough Device Designation
  • Comparative review of prior device and pharmaceutical approvals
  • Executive presentation

1. Landscape Mapping

I catalogued all ongoing clinical trials utilizing the device, spanning multiple therapeutic indications. For each, I assessed trial design, geographic scope, patient population, and alignment with FDA pivotal trial standards.

2. Comparative Analysis

Each indication was benchmarked against historical FDA approvals, both devices and pharmaceuticals, to evaluate precedent, competitive landscape, and the strength of the existing evidence base. I also assessed how each trial measured up against relevant FDA guidance documents.

3. Risk & Viability Evaluation

I scored each pathway on key factors:

  • predicate device availability
  • trial geography (US vs. ex-US)
  • unmet medical need
  • regulatory designation eligibility
  • submission readiness

This framework helped me identify a clear path to approval.

Outcome & Recommendation

My recommendation was to pursue a De Novo classification for Prader-Willi Syndrome, a rare condition with no approved medical device treatment and one previous pharmaceutical approval. The supporting clinical trial was US-based, a meaningful advantage for FDA submissions, and the absence of adequate existing therapies established a strong rationale for pursuing Breakthrough Device Designation, which can significantly accelerate review timelines. This represented the highest-probability, lowest-risk path to FDA Approval.

Findings were reported in an executive-facing presentation delivered to C-suite leadership, providing a prioritized regulatory roadmap and clear rationale for the recommended strategy.

← Back to work